Literature DB >> 9137974

Pathogenesis and management of bone lesions in multiple myeloma.

R Bataille1, S C Manolagas, J R Berenson.   

Abstract

Osteolytic lesions are among the hallmarks of multiple myeloma (MM). On the other hand, they are rare in B cell malignancies other than MM. Data have shown a close relationship between myeloma cell growth factors and factors involved in the occurrence of bone lesions in MM. Biophosphonates, which are potent inhibitors of bone resorption to control MM-induced hypercalcemia, are of interest due to their ability to slow the progression of MM bone disease.

Entities:  

Mesh：

Year:  1997        PMID： 9137974     DOI： 10.1016/s0889-8588(05)70435-4

Source DB:  PubMed          Journal:  Hematol Oncol Clin North Am        ISSN： 0889-8588            Impact factor:   3.722


  11 in total

1.  The phenotypic plasticity of myeloma plasma cells as expressed by dedifferentiation into an immature, resilient, and apoptosis-resistant phenotype.

Authors:  Shmuel Yaccoby
Journal:  Clin Cancer Res       Date:  2005-11-01       Impact factor: 12.531

Review 2.  Current drug therapy for multiple myeloma.

Authors:  Y W Huang; A Hamilton; O J Arnuk; P Chaftari; R Chemaly
Journal:  Drugs       Date:  1999-04       Impact factor: 9.546

3.  Role of 18F-FDG PET/CT in the assessment of bone involvement in newly diagnosed multiple myeloma: preliminary results.

Authors:  Cristina Nanni; Elena Zamagni; Mohsen Farsad; Paolo Castellucci; Patrizia Tosi; Delia Cangini; Eugenio Salizzoni; Romeo Canini; Michele Cavo; Stefano Fanti
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-02-02       Impact factor: 9.236

Review 4.  Presentation of multiple myeloma occurring in the humerus after strain: a case report.

Authors:  Ebru Yilmaz
Journal:  Clin Rheumatol       Date:  2020-07-01       Impact factor: 2.980

5.  Expression of CD56/neural cell adhesion molecule correlates with the presence of lytic bone lesions in multiple myeloma and distinguishes myeloma from monoclonal gammopathy of undetermined significance and lymphomas with plasmacytoid differentiation.

Authors:  Scott A Ely; Daniel M Knowles
Journal:  Am J Pathol       Date:  2002-04       Impact factor: 4.307

6.  Altered expression of fibronectin and collagens I and IV in multiple myeloma and monoclonal gammopathy of undetermined significance.

Authors:  Tara M Tancred; Andrew R Belch; Tony Reiman; Linda M Pilarski; Julia Kirshner
Journal:  J Histochem Cytochem       Date:  2008-11-11       Impact factor: 2.479

7.  Selection, Expansion, and Unique Pretreatment of Allogeneic Human Natural Killer Cells with Anti-CD38 Monoclonal Antibody for Efficient Multiple Myeloma Treatment.

Authors:  Benjamin Motais; Sandra Charvátová; Zuzana Walek; Matouš Hrdinka; Ryszard Smolarczyk; Tomasz Cichoń; Justyna Czapla; Sebastian Giebel; Michal Šimíček; Tomáš Jelínek; Tereza Ševčíková; Jiří Sobotka; Zdeněk Kořístek; Roman Hájek; Juli R Bagó
Journal:  Cells       Date:  2021-04-21       Impact factor: 6.600

8.  The systemic cytokine environment is permanently altered in multiple myeloma.

Authors:  Mary M Zheng; Zhifang Zhang; Kyle Bemis; Andrew R Belch; Linda M Pilarski; John E Shively; Julia Kirshner
Journal:  PLoS One       Date:  2013-03-27       Impact factor: 3.240

9.  Myeloma cells inhibit osteogenic differentiation of mesenchymal stem cells and kill osteoblasts via TRAIL-induced apoptosis.

Authors:  Jinxiang Fu; Panjun Wang; Xiaohui Zhang; Suguang Ju; Jie Li; Binzhou Li; Sun Yu; Jianhua Zhang; Xueguang Zhang
Journal:  Arch Med Sci       Date:  2010-09-07       Impact factor: 3.318

10.  Serum bone sialoprotein as a marker of tumour burden and neoplastic bone involvement and as a prognostic factor in multiple myeloma.

Authors:  H W Woitge; M Pecherstorfer; E Horn; A V Keck; I J Diel; P Bayer; H Ludwig; R Ziegler; M J Seibel
Journal:  Br J Cancer       Date:  2001-02-02       Impact factor: 7.640
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.